on TuHURA Biosciences, Inc.
TuHURA Biosciences to Present at ROTH Conference
TuHURA Biosciences, Inc. (NASDAQ:HURA), an immuno-oncology firm, announced participation in the 37th Annual ROTH Conference. James A. Bianco, CEO, will engage in a fireside chat on March 18, 2025, at 8:30 AM PT in Dana Point, CA. The event includes opportunities for one-on-one investor meetings. Further details are available on the conference website.
A live webcast of the discussion will be accessible via the company's website. TuHURA, currently in Phase 3 of registering its immune technology, is developing solutions to combat resistance in cancer immunotherapy.
The firm prepares to launch a Phase 3 trial for its drug IFx-2.0 against Merkel Cell Carcinoma. TuHURA also advances a VISTA inhibiting antibody, following a merger with Kineta, for AML treatment. Research on the Delta Opioid Receptor's immune role is underway.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all TuHURA Biosciences, Inc. news